Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

Authors :: Choueiri, Toni K.
Tomczak, Piotr
Park, Se Hoon
Venugopal, Balaji
Ferguson, Thomas
Symeonides, Stefan N.
Hajek, Jaroslav
Chang, Yen-Hwa
Lee, Jae-Lyun
Sarwar, Naveed
Gurney, Howard
Gross-Goupil, Marine
Mahave, Mauricio
Haas, Naomi B.
Sawrycki, Piotr
Zhang, Tian
Cornell, Jerry
Elfiky, Aymen
Burgents, Joseph E.
Powles, Thomas
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pLBA359-LBA359, 6p
Publication Year :: 2024

Full Text Access

Tools